Поиск | ZirVeDe

Rutuja Bhosale добавлена новая статья Networking
2026-04-01 07:23:10 -

Ultomiris Drug Market Size, Share & Forecast 2026–2034
Ultomiris Drug Market Dynamics: Opportunities, Risks & Forecast Ultomiris Drug Market Market Overview The Global Ultomiris Drug Market is witnessing strong growth, driven by rising demand for advanced therapies targeting rare and life-threatening diseases. The market is projected to grow from USD 5.2 billion in 2025 to USD 14.9 billion by 2033, registering a CAGR...

0 Комментарии 0 Поделились 280 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Rutuja Bhosale добавлена новая статья Networking
2026-04-14 06:44:09 -

Ultomiris Market Trends Growth, Demand, and Future Outlook
Ultomiris Drug Market Dynamics: Opportunities, Risks & Forecast Market Overview The Global Ultomiris Drug Market is witnessing strong growth, driven by rising demand for advanced therapies targeting rare and life-threatening diseases. The market is projected to grow from USD 5.2 billion in 2025 to USD 14.9 billion by 2033, registering a CAGR of 14.4% during the...

0 Комментарии 0 Поделились 165 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Rutuja Bhosale добавлена новая статья Networking
2026-04-14 06:44:27 -

Ultomiris Market Trends Growth, Demand, and Future Outlook
Ultomiris Drug Market Dynamics: Opportunities, Risks & Forecast Market Overview The Global Ultomiris Drug Market is witnessing strong growth, driven by rising demand for advanced therapies targeting rare and life-threatening diseases. The market is projected to grow from USD 5.2 billion in 2025 to USD 14.9 billion by 2033, registering a CAGR of 14.4% during the...

0 Комментарии 0 Поделились 168 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Rutuja Bhosale добавлена новая статья Networking
2026-04-30 05:19:36 -

Ultomiris Market Trends, Growth Drivers, and Future Outlook (2026–2033)
Ultomiris Drug (ravulizumab) Market is a long-acting monoclonal antibody developed to treat rare complement-mediated disorders. As a C5 complement inhibitor, it plays a critical role in managing diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder...

0 Комментарии 0 Поделились 140 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!